The company's shares fell 3.5% in volatile premarket trading on Monday as Pfizer said it would stop developing its therapy lotiglipron.
"The expectation of weight loss from being overweight to a normal weight with the help of a diet is almost never realistic,” asserts Dr. Irit Hochberg
JPOST Digital Library
